Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI)

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 709-714

  Sekine, I ^a   Nishiwaki, Y ^b   Noda, K ^c   Kudoh, S ^d   Fukuoka, M ^e   Mori, K ^f   Negoro, S ^g   Yokoyama, A ^h   Matsui, K ⁱ   Ohsaki, Y ^j   Nakano, T ^k   Saijo, N ^k  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOCHIGI CANCER CENTER   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h NIIGATA CANCER CENTER HOSPITAL   (Japan)

ⁱ OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^j ASAHIKAWA MEDICAL COLLEGE   (Japan)

^k HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

Cisplatin; Etoposide; Irinotecan; Randomized phase II; Small cell lung cancer

Indexed keywords

ANTIARRHYTHMIC AGENT; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHLEGMON; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038443986     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg213     Document Type: Article

References (19)

1. Sekine I, Kodama T, Yokose T et al. Rare pulmonary tumors - a review of 32 cases. Oncology 1998; 55: 431-434.
2. Sekine I, Nishiwaki Y, Kakinuma R et al. Late recurrence of small-cell lung cancer: treatment and outcome. Oncology 1996; 53: 318-321.
3. Evans WK, Shepherd FA, Feld R et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985; 3: 1471-1477.
4. Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-861.
5. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
6. Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-1229.
7. Kudoh S, Fujiwara Y, Takada Y et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16: 1068-1074.
8. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive disease small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
9. Sekine I, Nishiwaki Y, Kakinuma R et al. Phase I/II trial of weekly cisplatin, etoposide and irinotecan for metastatic lung cancer (JCOG STUDY 9507). Proc Am Soc Clin Oncol 1998; 17: 1926a (Abstr).
10. Tsukada H, Yokoyama A, Kurita Y et al. Phase I/II trial of cisplatin, etoposide, and irinotecan for the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19: 517a (Abstr).
11. Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-257.
12. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: WHO 1979.
13. Simon R, Wittes RE, Ellenberg SS. Ransomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375-1381.
14. Longo DL, Duffey PL, DeVita VT Jr et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991; 9: 2042-2051.
15. Armitage P, Berry G. Survival analysis. In Statistical Methods in Medical Research, 3rd edition. Oxford, UK: Blackwell Scientific Publications 1994; 469-492.
16. Souhami RL, Rudd R, de Elvira MCR et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994; 12: 1806-1813.
17. Furuse K, Fukuoka M, Nishiwaki Y et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998; 16: 2126-2132.
18. Murray N, Livingston R, Shepherd F et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trial Group and Southwest Oncology Group. J Clin Oncol 1999; 17: 2300-2308.
19. Soto Parra HJ, Cavina R, Antonelli G et al. Superiority of three-week vs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): results of a randomized phase II study. Proc Am Soc Clin Oncol 2000; 19: 546a (Abstr).